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Statement of translational relevance 
 
Immune checkpoint inhibitors are approved or in advanced development for 
several types of cancer. To expand the clinical benefit of this approach, 
agents designed to target other immunoregulatory receptors are under clinical 
evaluation, including agonist antibodies against co-stimulatory molecules such 
as CD137. The manuscript reports safety, tolerability, and pharmacodynamic 
activity data from three studies evaluating urelumab, an agonist anti-CD137 
monoclonal antibody, and includes information on the hepatotoxicity 
observed. The data showed that urelumab dose was the single most 
important factor contributing to the development of severe transaminitis, with 
significant transaminitis strongly associated with doses ≥1 mg/kg. In addition, 
urelumab 0.1 mg/kg every 3 weeks was demonstrated to be safe, with 
pharmacodynamic activity supporting the continued clinical evaluation of this 
dose as monotherapy and in combination with other immuno-oncology 
agents. 
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ABSTRACT  
Purpose 
Urelumab is an agonist antibody to CD137 with potential application as an immuno-
oncology therapeutic. Data were analyzed to assess safety, tolerability, and 
pharmacodynamic activity of urelumab, including the dose selected for ongoing 
development in patients with advanced solid tumors and lymphoma. 
Patients and methods      
Three hundred and forty-six patients with advanced cancers who had progressed 
after standard treatment received at least one dose of urelumab in one of three dose-
escalation, monotherapy studies. Urelumab was administered at doses ranging from 
0.1 to 15 mg/kg. Safety analyses included treatment-related and serious adverse 
events (AEs), as well as treatment-related AEs leading to discontinuation and death, 
with a focus on liver function test abnormalities and hepatic AEs.   
Results 
Urelumab doses between 1 and 15 mg/kg given every 3 weeks (Q3W) resulted in a 
higher frequency of treatment-related AEs than 0.1 or 0.3 mg/kg Q3W. Dose was the 
single most important factor contributing to transaminitis development, which was 
more frequent and severe at doses ≥1 mg/kg. At the maximum tolerated dose of 
0.1 mg/kg Q3W, urelumab was relatively well tolerated, with fatigue (16%) and 
nausea (13%) being the most common treatment-related AEs, and was associated 
with immunologic and pharmacodynamic activity demonstrated by the induction of 
interferon-inducible genes and cytokines. 
Conclusion 
Integrated evaluation of urelumab safety data showed significant transaminitis was 
strongly associated with doses of ≥1 mg/kg. However, urelumab 0.1 mg/kg Q3W was 
demonstrated to be safe, with pharmacodynamic activity supporting continued 
Research. 
on December 1, 2017. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 18, 2016; DOI: 10.1158/1078-0432.CCR-16-1272 
6 
 
clinical evaluation of this dose as monotherapy and in combination with other 
immuno-oncology agents. 
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INTRODUCTION  
Agents designed to block the inhibitory immune checkpoints cytotoxic T lymphocyte 
antigen 4 (CTLA-4) and programmed death 1 (PD-1) are approved for advanced 
melanoma (alone and in combination), and anti-PD-1 is approved for non-small cell 
lung cancer and renal cell carcinoma (1). Both anti-CTLA-4 and anti-PD-1 can elicit 
durable clinical responses and, in some patients, result in long-term remissions with 
no clinical evidence of cancer (2-4). To expand the clinical benefit of this approach, 
agents designed to target other immunoregulatory pathways are under evaluation, 
including antagonists of inhibitory checkpoints such as LAG-3 and TIM-3, but also 
agonist antibodies against co-stimulatory molecules on immune cells such as CD137 
(4-1BB), CD40, GITR, and OX-40 (5-7). 
CD137 is a co-stimulatory member of the tumor necrosis factor (TNF) receptor 
superfamily that is expressed on a variety of immune cells following activation, 
including T cells, dendritic cells, and natural killer cells. Signaling via CD137 can lead 
to cytokine induction, prevention of activation-induced cell death, and upregulation of 
cytotoxic T-cell activity; CD137 may also reduce the infiltration of regulatory T cells 
into tumors (8, 9). Melero and colleagues were the first to report that agonist 
monoclonal antibodies (mAbs) to CD137 eradicated large, established tumors in 
mice. The long-lasting antitumor activity seen in their model was primarily mediated 
by CD8+ T cells and associated with memory responses (10).  
Two mAbs to CD137 have been developed and are undergoing clinical evaluation. 
Urelumab (BMS-663513, clone 10C7; Bristol-Myers Squibb) is an agonist, non-
ligand-blocking, fully human mAb, engineered as an IgG4 to reduce binding to Fc 
receptors with a hinge mutation (S228P) to improve stability (11-13). PF-05082566 
(Pfizer) is a fully human IgG2 mAb (14). In preclinical studies, urelumab enhanced 
interferon gamma (IFN-γ) production, T-cell survival, and the cytolytic activity of 
antigen-specific T cells (11, 13, 15), as expected for an antibody with co-stimulatory 
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activity. Urelumab entered clinical development in 2005 and was evaluated as a 
monotherapy in two studies, CA186-001 (NCT00309023) and CA186-006 
(NCT00612664). In December 2008, enrollment was stopped for all urelumab studies 
following the occurrence of two hepatotoxicity-related deaths. Subsequent detailed 
analysis of the clinical safety data demonstrated that urelumab dose was the single 
most important factor contributing to the development of severe transaminitis. The 
urelumab clinical development program was re-started with study CA186-011 
(NCT01471210) in February 2012 to evaluate monotherapy doses <1 mg/kg (16). 
Subsequently, three urelumab-based combination studies were opened from March 
2013 onward.  
Here we report integrated safety and preliminary pharmacodynamic data from 
urelumab monotherapy studies CA186-001 (NCT00309023), CA186-006 
(NCT00612664), and CA186-011 (NCT01471210). 
PATIENTS AND METHODS 
Patients and Study Design 
Aggregated data from patients participating in three urelumab studies were included 
in this analysis. For all studies, patients provided written, informed consent; protocols 
were approved by the relevant institutional review boards and independent ethics 
committees; and conduct was in accordance with International Conference on 
Harmonization guidelines on Good Clinical Practice and the principles of the 
Declaration of Helsinki. 
Study CA186-001 (-001) was an open-label, ascending, multidose, phase 1/2 study 
of urelumab in patients with metastatic or locally advanced solid malignancies who 
had disease progression on standard therapy or refused or were unable to receive 
standard treatment. Patients were assigned to 1 of 6 sequential cohorts to receive 
urelumab 0.3, 1, 3, 6, 10, or 15 mg/kg every 3 weeks (Q3W). The primary study 
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objective was to assess safety and tolerability of urelumab, and secondary objectives 
included assessing pharmacokinetics (PK), relationship between dose and biologic 
effect, and antitumor activity (11). 
Study CA186-006 (-006) was a randomized, multidose, open-label, parallel 4-arm, 
phase 2 study in patients with stage III/IV melanoma who had received one line of 
prior systemic treatment with any regimen (nonexperimental or experimental) and 
relapsed, progressed, or did not tolerate that regimen. Patients were randomized to 
receive urelumab at 0.1, 1, or 5 mg/kg Q3W or 1 mg/kg every 6 weeks (Q6W). The 
primary objective was to determine the 6-month progression-free survival rate in 
each arm. Secondary objectives included assessment of the tumor response rate, 
safety profile, and PK and pharmacodynamic parameters. 
Study CA186-011 (-011) is an ongoing phase 1 study that included dose escalation 
(part 1) using a 6 + 9 design, cohort expansion (part 2), and tumor-specific cohort 
expansion (part 3). In part 1, successive cohorts of patients with advanced and/or 
metastatic solid tumors were treated as follows: cohort 1 with 0.1 mg/kg Q3W and 
cohort 2 with 0.3 mg/kg Q3W. In part 2, both cohorts (1 + 2) were expanded to 
20 patients with advanced solid tumors. In part 3, additional tumor-specific cohorts 
with B-cell non-Hodgkin's lymphoma, colorectal cancer, and head and neck cancer 
(10 patients each) were enrolled at the highest tolerated dose of 0.3 mg/kg Q3W. 
The primary objective was to evaluate safety and define dose-limiting toxicity and 
maximum tolerated dose of urelumab; secondary objectives included assessment of 
preliminary antitumor activity, PK, and immunogenicity.  
Assessments 
In all studies, safety was evaluated using the National Cancer Institute Common 
Terminology Criteria for Adverse Events (v3.0 in -001 and -006, and v4 in -011). 
Adverse events (AEs) were mapped to preferred term and body system using the 
Medical Dictionary for Regulatory Activities. Safety assessments were based on 
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medical review of AE reports, vital sign measurements, physical examinations, and 
clinical laboratory tests. 
Serum samples were collected to characterize urelumab PK and immunogenicity 
after multiple doses. The noncompartmental analysis and population PK analysis 
were used to estimate PK parameters and derive an individual estimate of the 
average concentration at steady state (Cavgss) in a total of 333 patients for 
exposure-response analysis (see Methods Supplement and Supplementary Tables 
1 and 2). Blood samples for pharmacodynamic assessments were collected at 
prespecified time points from consenting patients (n = 32).  
Data Analysis 
All patients treated in studies -001 and -006 were included in the analysis, as well as 
patients treated up to a data cutoff of September 26, 2014 from study -011. Three 
hundred and forty-six patients received at least one dose of urelumab and were 
evaluable for safety. An integrated safety analysis determined the incidence of all 
treatment-related AEs, including serious AEs (SAEs), and treatment-related AEs 
leading to discontinuation and death. A detailed analysis of liver function test (LFT) 
results (alanine aminotransferase [ALT], aspartate aminotransferase [AST], and total 
bilirubin [Tbili]) was performed considering toxicity grade, dose level, and cycle for 
each study. Possible alternative causes for transaminitis were also evaluated.  
 
RESULTS 
Patient Characteristics 
Between 2005 and 2008, 115 patients were enrolled and treated in -001; 159 
patients were enrolled into -006, 158 of whom received urelumab; and between 2011 
and 2014, 73 patients were enrolled and treated in -011. Baseline demographics for 
all enrolled patients (N = 347) are shown (Table 1).  
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Overview of Treatment-Related AEs 
Across all studies, urelumab doses between 1 and 15 mg/kg resulted in a higher 
frequency of treatment-related AEs than doses of 0.1 or 0.3 mg/kg (Table 2). At 
doses ≥1 mg/kg, the most frequent treatment-related AEs were increased AST 
(27%), increased ALT (27%), and fatigue (24%), although there was no evidence of 
dose dependency. At 0.3 mg/kg, increased AST and fatigue were the most frequent 
treatment-related AEs (both 14%), and at 0.1 mg/kg, fatigue (16%) and nausea 
(13%) were the most common treatment-related AEs. Grade 3 or higher treatment-
related AEs were more frequent at urelumab doses of 1 to 15 mg/kg than at the 0.1 
and 0.3 mg/kg doses (Table 2).  
There was a similar pattern for treatment-related SAEs, with the majority occurring at 
doses ≥1 mg/kg and the most common being increased ALT, increased AST, and 
fatigue (Table 2). At 0.3 mg/kg there were 7 treatment-related SAEs (2 increased 
ALT, 2 increased AST, 1 abnormal LFT, 1 acute hepatitis, and 1 enteritis). There 
were 2 treatment-related SAEs at 0.1 mg/kg: increased ALT and erysipelas (Table 
2). 
The rate of patient discontinuation due to a treatment-related AE was higher with 
urelumab ≥1 mg/kg compared with 0.1 and 0.3 mg/kg. At ≥1 mg/kg, 37 of 229 
patients (16%) discontinued due to a treatment-related AE; at 0.3 mg/kg, 5 of 56 
patients (9%) discontinued; and at 0.1 mg/kg, 7 of 61 patients (11%) discontinued. 
Two deaths occurred at the higher dose range (1 and 5 mg/kg, respectively). Both 
deaths were attributed to drug-related hepatotoxicity and the patients were enrolled 
in study -006 in the 1 mg/kg Q3W and 5 mg/kg Q3W arms, respectively. Neither 
patient was taking concomitant medications with known potential for hepatotoxicity, 
and both received immunosuppressant medication for management. Postmortem 
examination was conducted in only 1 of the 2 patients and was noncontributory. One 
Research. 
on December 1, 2017. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 18, 2016; DOI: 10.1158/1078-0432.CCR-16-1272 
12 
 
patient treated with urelumab monotherapy at 6 mg/kg who developed severe 
transaminase elevations and hyperbilirubinemia also underwent a liver biopsy; 
histopathology examination was consistent with bile duct injury consistent with drug-
related liver injury, with only a moderate mixed inflammatory infiltrate containing 
lymphocytes and other inflammatory cells including neutrophils. 
Of note, the patient in the 1 mg/kg Q3W arm had previously been treated with a 
monoclonal antibody to CTLA-4 and had developed one immune-related AE, 
panhypopituitarism, while on prior treatment with CTLA-4 blockade. 
Transaminitis 
Transaminitis was more frequent at urelumab doses ≥1 mg/kg (Table 3). Exposure-
response analyses demonstrated a correlation between the occurrence and severity 
of transaminitis with exposure (average observed concentration [Cavg]), and 
suggested that the risk of developing clinically relevant transaminitis may be 
substantially increased at exposures (higher Cavg) achieved with urelumab doses 
≥1 mg/kg Q3W (Figure 1). 
Correlative analyses of data from studies -001 and -006 (n = 270) were performed to 
assess whether certain clinical features (liver function abnormalities at baseline, 
baseline liver metastases, and acetaminophen or statin use on study) could predict 
which patients were more likely to experience transaminitis with urelumab across the 
dose range evaluated. There was no clear association between AST or ALT 
abnormality (grade ≥1) at baseline and increased AST or ALT of grade ≥3, nor was 
there any association between baseline liver metastases or acetaminophen or statin 
use while on study and increased AST or ALT of grade ≥2 (data not shown).  
Rechallenge after transaminase elevation. Twenty-five patients who developed 
increased AST, ALT, and/or Tbili of grade ≥2 were rechallenged with urelumab. 
Patients were rechallenged with the same dose of urelumab, except one patient who 
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received a lower dose. Of these, 15 patients (60%) did not have recurrence of grade 
≥2 LFT AE. This group included one patient at 0.1 mg/kg and two patients at 
0.3 mg/kg; the remaining 12 patients were receiving urelumab at ≥1 mg/kg, including 
one patient at 10 mg/kg. Ten of the patients who were rechallenged had recurrence 
of grade ≥2 LFT AE; 5 of these patients (1 at 0.3 mg/kg and the remainder at 1 
mg/kg) continued urelumab treatment and 5 discontinued treatment for reasons other 
than toxicity (all at ≥1 mg/kg). Two patients with grade 3 or 4 ALT or AST elevations 
were re-treated with the original treatment dose of 1 mg/kg after laboratory values 
returned to below the upper limit of normal. Both patients tolerated re-treatment, with 
ALT and AST fluctuating between normal and grade 2. No patient discontinued study 
drug due to an AE upon rechallenge. 
Management of transaminitis. In study -011, patients with grade 2 transaminitis AEs 
were managed by withholding urelumab treatment until the AEs were grade ≤1. 
Patients with grade 3 or higher AEs received treatment with systemic corticosteroids 
and discontinued urelumab. All of the 3 patients in -011 with grade 3 increased 
AST/ALT who received corticosteroids responded to treatment and were not 
rechallenged with urelumab. 
Cytopenias  
Laboratory evaluations showed grade 1 to 4 reductions in absolute neutrophil, 
platelet, and leukocyte counts across the dose range evaluated (Table 4). Most AEs 
were grade 1 or 2 in severity; the 0.1 mg/kg dose was associated with the lowest 
frequency of these AEs. Leukopenia and neutropenia events were not associated 
with infections, nor were there any episodes of bleeding related to thrombocytopenia 
(see prior section). Febrile neutropenia was not reported in any patient who received 
<1 mg/kg (4 events reported at doses ≥1 mg/kg; Table 2). 
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Pharmacokinetics  
The observed serum concentration:time profile across the dose range evaluated is 
shown in Supplementary Figure 1. The PK of single-agent urelumab was studied 
over the range of 0.1 to 15 mg/kg administered as multiple doses Q3W and one 
cohort at 1 mg/kg Q6W. Urelumab exposure increased dose proportionally across 
the studied dose range. The half-life of urelumab was estimated from population PK 
to be approximately 18 days, with the minimum concentration (Cmin) at steady state 
being greater than the pharmacologically active exposure level based on the in vitro 
human T-cell binding affinity of 0.1 µg/mL (data not shown).  
Pharmacodynamic Activity 
Treatment with urelumab 0.1 mg/kg induced a range of IFN-induced cytokines 
(Figure 2) and IFN-response genes (Supplementary Figure 2). The level of several 
IFN-induced cytokines was increased in serum at 1 week after urelumab 
administration (day 8 samples were not collected; day 29 was 1 week after the 
second dose); similarly the expression of several IFN-response genes was increased 
in whole blood samples at approximately 3 and/or 7 days following urelumab 
administration and appeared to return to pretreatment levels by day 22. 
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DISCUSSION 
The co-stimulatory receptor CD137 is a promising target for cancer immunotherapy 
(8, 9). This integrated safety analysis is one of the first reports of an agonist mAb 
targeting CD137. Overall safety data from evaluation of urelumab at doses of 0.1 to 
15 mg/kg across three studies support 0.1 mg/kg Q3W as the maximum tolerated 
dose. Experience with urelumab at 0.1 mg/kg Q3W in 61 patients with advanced 
malignancies demonstrated acceptable safety and tolerability, and pharmacodynamic 
activity consistent with immune activation. The significant transaminitis that led to the 
suspension of the clinical program was strongly associated with exposure to 
urelumab at doses of 1 mg/kg and above, suggesting a reasonable separation 
between the potential efficacious dose and the doses associated with toxicity. 
Doses ≥1 mg/kg were associated with a high incidence of moderate to severe 
hepatic toxicity (ranging from asymptomatic increases in laboratory measures of 
LFTs to hepatic failure). Outcomes from analysis of LFTs and hepatic AEs showed 
that transaminitis was strongly associated with exposure to urelumab ≥1 mg/kg. In 
contrast, doses <1 mg/kg Q3W were associated with the lowest probability of severe 
transaminitis and generally a low frequency of other AEs—predominantly grade 1 or 
2 AEs. Accordingly, the clinical program was re-started to investigate 0.1 and 0.3 
mg/kg Q3W doses and included a clinical safety plan to monitor and manage 
transaminitis. Concomitant transaminitis (grade 4 increased AST and ALT) and 
hyperbilirubinemia (grade 3 increased Tbili) were reported in a single patient 
receiving 0.3 mg/kg in study -011; this dose was deemed to have exceeded the 
maximum tolerated dose and further investigation of 0.3 mg/kg was stopped. 
Although hepatotoxicity in this patient resolved following treatment with 
immunosuppressive therapy per protocol-specified guidelines, further investigation of 
the 0.3 mg/kg dose was stopped, and the urelumab dose was reduced to 0.1 mg/kg 
Q3W in all patients.  
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No risk factor predisposing patients to developing transaminitis was identified in the 
integrated safety analysis of the completed studies -001 and -006 (n = 169). Although 
the evaluation of data from study -011 is ongoing, preliminary evaluation is similarly 
consistent with no identifiable risk factor for transaminitis.  
Most of the patients who had their treatment withheld because of grade 2 
transaminitis were able to resume treatment at the same dose with no recurrence of 
these AEs. Experience gained managing transaminitis in studies -001, -006, and -
011, and in managing transaminitis induced by other immune checkpoint inhibitors, 
contributed to the development of the management strategies included in current 
urelumab study protocols. In general, patients receiving urelumab require close 
monitoring of LFTs. For grade 2 LFT AEs, urelumab dosing was delayed, alternative 
causes were investigated, and LFTs were monitored at increased frequency; for 
grade 3 or 4 AEs or grade 2 events that were worsening or persisting for more than 5 
to 7 days, urelumab was discontinued, LFTs were monitored at increased frequency, 
and corticosteroids were administered.   
Observations in murine models provide a possible explanation for liver-related AEs 
associated with agonist CD137 mAbs. Liver lymphocyte infiltration was reported in 
several studies of mice treated with a mouse anti-CD137 mAb (17-19). While 
preliminary data from preclinical toxicity models suggest hepatic infiltration by 
lymphocytes (following crosslinking of CD137 receptor) as being possibly involved in 
producing liver toxicity, additional preclinical studies are ongoing to further address 
the mechanism of action of urelumab-related AEs (Bristol-Myers Squibb, unpublished 
data).  
Aside from transaminitis, urelumab was not associated with the immune-mediated 
AEs commonly reported with CTLA-4 and PD-1/PD-L1 immune checkpoint inhibitors 
that affect the gastrointestinal, skin, pulmonary, and endocrine systems (20). 
Neutropenia, which is uncommon with CTLA-4 and PD-1 immune checkpoint 
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inhibitors (20), was observed with urelumab. Drug-related febrile neutropenia was not 
noted at the urelumab maximum tolerated dose.  
Although the mechanism of urelumab-related neutropenia is a matter of ongoing 
investigation, data from a murine model of listeria showed that CD137-mediated 
stimulation of neutrophils in early infection caused rapid production of inflammatory 
cytokines/chemokines and subsequent infiltration of neutrophils and monocytes 
crucial for eliminating the infecting bacteria (21).  
The clinical evaluation of urelumab is ongoing at 0.1 mg/kg Q3W as monotherapy 
and in combination with targeted mAbs, cetuximab, rituximab, or elotuzumab 
(NCT01775631, NCT02110082, and NCT02252263). This approach is based on 
preclinical data that showed enhancement of antibody-dependent cellular cytotoxicity 
when an agonist CD137 mAb was given after a targeted mAb (22-24). A study is also 
in progress to evaluate urelumab in combination with nivolumab, an anti-PD-1 
immune checkpoint inhibitor, in patients with advanced solid tumors and B-cell non-
Hodgkin's lymphoma (NCT02253992). Preclinical data suggest that combined 
targeting of co-stimulatory and inhibitory immune checkpoint pathways may enhance 
antitumor immune responses and prolong survival, and could reduce the incidence of 
immune-mediated AEs, including liver inflammation (17, 25-27). 
In summary, urelumab at 0.1 mg/kg Q3W is well tolerated with evidence of 
immunologic activity. Clinical studies evaluating urelumab as monotherapy and in 
combination with other immuno-oncology agents are ongoing. 
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Table 1. Patient Demographics  
 Study -001  
n = 115a 
Study -006  
n = 159b,c 
Study -011  
n = 73 
Median age, years 
  <65 years, % 
  ≥65 years, % 
61.0 
65 
35 
59.0 
65.4 
34.6 
60.0 
67.1 
32.9 
Sex, % 
  Male  
  Female 
 
53 
47 
 
59 
41 
 
55 
45 
ECOG PS, % 
  0 
  1 
  2 
 
51 
44 
0 
 
77c 
20 
2 
 
40 
59 
0 
Race, % 
  White 
  Other 
 
97 
3 
 
99 
1 
 
93 
7 
Tumor type, % 
  Melanoma 
  Kidney 
  Ovary 
  Pancreas 
  Prostate 
  NSCLC 
  Head and neck 
  Colorectal 
  NHL 
 
48 
23 
24 
0 
1 
0 
0 
0 
0 
 
100 
0 
0 
0 
0 
0 
0 
0 
0 
 
8 
4 
1 
1 
0 
15 
21 
22 
11 
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aPS data not available for 5 patients in study -001. 
bData are for all randomized patients; 1 patient was randomized but not treated. 
cPS data not available for 1 patient in study -006. 
Abbreviations: ECOG-PS, Eastern Cooperative Oncology Group performance status; NHL, non-
Hodgkin’s lymphoma; NSCLC, non-small cell lung cancer. 
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Table 2. Investigator-Reported Treatment-Related Adverse Eventsa and Serious Adverse Eventsb  
Event  
Urelumab 
0.1 mg/kg  
(n = 61)c 
Urelumab 
0.3 mg/kg  
(n = 56)c 
Urelumab  
≥1 mg/kg  
(n = 229)c 
Any grade ≤4 AEsa, % 
(grade 3-4, %)d    
AST increased 8.2 14.3 (3.6) 27.1 (13.5) 
ALT increased 6.6 (1.6) 10.7 (3.6) 26.6 (16.6) 
Fatigue 16.4 14.3 24.0 
Rash 4.9 7.1 19.7 
Nausea 13.1 3.6 13.5 
Pruritus 4.9 5.4 13.1 
Decreased appetite 8.2 3.6 12.2 
Pyrexia 4.9 1.8 12.2 
Diarrhea 3.3 3.6 12.2 
R
esearch. 
o
n
 D
ecem
ber 1, 2017. © 2016 Am
erican Association for Cancer
clincancerres.aacrjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on O
ctober 18, 2016; DO
I: 10.1158/1078-0432.CCR-16-1272 
26 
 
Asthenia 8.2 0 7.9 
Headache 1.6 1.8 7.0 
Neutropenia 4.9 (3.3) 0 6.1 (2.6) 
Vomiting 3.3 0 5.2 
Any grade ≤4 SAEsa, 
% (grade 3-4, %)d    
ALT increased 1.6 3.6 (3.6) 5.2 (5.2) 
AST increased  3.6 (3.6) 4.8 (4.4) 
Neutropenia   3.1 (3.1) 
Thrombocytopenia   2.2 (1.3) 
Febrile neutropenia 1.6 (1.6)e  1.7 (1.7) 
Cellulitis   1.3 (0.9) 
Anemia   0.9 (0.4) 
Leukopenia   0.9 (0.9) 
Fatigue   0.9 (0.4) 
Nausea   0.4 (0.4) 
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Decreased appetite   0.4 (0.4) 
Pyrexia   0.4 (0.4) 
Increased blood 
bilirubin   0.4 (0.4) 
Abnormal LFT  1.8 (1.8) 0.4 (0.4) 
Abdominal pain   0.4 (0.4) 
Hepatic failure   0.4 (0.4) 
Hyperbilirubinemia   0.4 (0.4) 
Anaphylactic shock   0.4 (0.4) 
Decreased neutrophil 
count   0.4 (0.4) 
Acute hepatitis 
Erysipelas 
Enteritis 
1.6 
 
1.8 (1.8) 
 
1.8  
Grade 5 SAEsa    
Malignant neoplasm   0.4 
R
esearch. 
o
n
 D
ecem
ber 1, 2017. © 2016 Am
erican Association for Cancer
clincancerres.aacrjournals.org 
D
ow
nloaded from
 
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author M
anuscript Published O
nlineFirst on O
ctober 18, 2016; DO
I: 10.1158/1078-0432.CCR-16-1272 
28 
 
progression 
Autoimmune hepatitis   0.4 
aData shown are for treatment-related AEs occurring in ≥5% patients in any dose group; all grade 3, 4, and 5 SAEs and grade 1 or 2 SAEs reported more than once are shown. 
Please note that the classification of AEs as either treatment-related or serious (both of which are presented in this table) is different, per the criteria defined in the protocols. 
bData are from the 346 patients who received at least 1 dose of urelumab. 
cPatients received urelumab Q3W, except 40 patients from study -006 who received 1 mg/kg Q6W. 
dAbsence of parentheses indicates no grade 3-4 AEs or SAEs were reported. 
eFebrile neutropenia was deemed to be unrelated to urelumab after the data cutoff date for this report. 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; SAEs, serious adverse events. 
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Table 3. Treatment-Related Abnormal Liver Function Test Laboratory Values by Dosea 
 Urelumab dose 
 0.1 mg/kg (n = 61)b 0.3 mg/kg (n = 56)b ≥1 mg/kg (n = 229)b 
ALT, n (%)    
Total grade 1−4 19 (31) 28 (50) 135 (59) 
Grade 1 18 (30) 21 (38) 63 (28) 
Grade 2 1 (2) 3 (5) 28 (12) 
Grade 3 0 3 (5) 27 (12) 
Grade 4 0 1 (2) 17 (7) 
AST, n (%)    
Total grade 1−4 23 (38) 29 (52) 136 (59) 
Grade 1 22 (36) 21 (38) 79 (34) 
Grade 2 0 4 (7) 18 (8) 
Grade 3 1 (2) 3 (5) 29 (13) 
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Grade 4 0 1 (2) 10 (4) 
Total bilirubin, n (%)    
Total grade 1−4 10 (16) 3 (5) 40 (18) 
Grade 1 10 (16) 1 (2) 22 (10) 
Grade 2 0 1 (2) 9 (4) 
Grade 3 0 1 (2) 5 (2) 
Grade 4 0 0 4 (2) 
aData are from the 346 patients who received at least 1 dose of urelumab. 
bPatients received urelumab Q3W, except 40 patients from study -006 who received 1 mg/kg Q6W. 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.  
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Table 4. Treatment-Related Abnormal Hematology Laboratory Values by Dosea 
 Urelumab dose 
 0.1 mg/kg (n = 61)b 0.3 mg/kg (n = 56)b ≥1 mg/kg (n = 229)b 
Absolute neutropenia, n (%)    
Total grade 1-4 14 (23) 19 (34) 64 (28) 
Grade 1 6 (10) 9 (16) 28 (12) 
Grade 2 3 (5) 3 (5) 13 (6) 
Grade 3 2 (3) 3 (5) 7 (3) 
Grade 4 3 (5) 4 (7) 16 (7) 
Thrombocytopenia, n (%)    
Total grade 1-4 12 (20) 25 (45) 63 (28) 
Grade 1 7 (11) 24 (43) 46 (20) 
Grade 2 3 (5) 0 7 (3) 
Grade 3 1 (2) 0 7 (3) 
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Grade 4 0 1 (2) 3 (1) 
Leukopenia, n (%)    
Total grade 1-4 10 (33) 19 (34) 84 (37) 
Grade 1 13 (21) 8 (14) 50 (22) 
Grade 2 2 (3) 5 (9) 15 (7) 
Grade 3 4 (7) 4 (7) 14 (6) 
Grade 4 1 (2) 2 (4) 5 (2) 
aData from the 344 patients; data not available from 2 patients who received urelumab ≥1 mg/kg. 
bPatients received urelumab Q3W, except 40 patients from study -006 who received 1 mg/kg Q6W. 
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FIGURE LEGENDS 
Fig 1. Exposure-response analysis of urelumab transaminitis.* The solid line 
represents model-estimated proportion of patients with LFT elevations at grade 1, 2, 
or 3 shown as blue, green, and orange lines, respectively. The observed proportion 
of patients with LFT elevations at grade 1, 2, or 3 and above is represented by solid 
points at the median Cavg for each tested dose level. Horizontal box and whisker 
plots show Cavg distribution at 0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg. Abbreviations: 
Cavg, average concentration; Gr, grade; LFT, liver function test; ss, steady state. *n 
= 333. 
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Fig 2. Induction of a range of IFN-induced cytokines at 0.1 mg/kg urelumab. 
Interferon-induced cytokines including interleukin-8 (IL-8), interferon-γ-inducible 
protein 10 (IP-10), monokine induced by IFN-γ (MIG or CXCL9), and macrophage 
inflammatory protein-1β (MIP-1β) were measured in the serum of 19 patients from 
study -011 who received urelumab 0.1 mg/kg. Percentage change from baseline for 
each cytokine was plotted.* Arrows indicate treatment days. Samples collected on 
treatment days were collected predose. Abbreviations: count, number of samples 
tested per time point; median, the quantity lying at the midpoint of a frequency 
distribution of observed values or quantities; Avg (abbreviation for average), the 
result obtained by adding together several quantities and then dividing this total by 
the number of quantities. *One outlier data point for IL-8 day 22 had a 2220% 
change from baseline and is off the scale of this graph, but is incorporated into the 
summary statistics table shown below the box plots.   
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